IMPROVED TRANSDERMAL DELIVERY SYSTEM
    2.
    发明授权
    IMPROVED TRANSDERMAL DELIVERY SYSTEM 有权
    改进的透皮给药系统

    公开(公告)号:EP1524971B1

    公开(公告)日:2006-10-25

    申请号:EP03766330.9

    申请日:2003-07-28

    申请人: SCHWARZ PHARMA AG

    IPC分类号: A61K9/70 A61K31/38

    摘要: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed priorto use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1)wherein an amine functional drug in its free base form has been incorporated, (2) which is saturated with the aminefunctional drug and contains said drug as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of the amine functional drug, (4) which is impermeable for the protonated form of the amine functional drug, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of the amine functional drug across the TDS/skin interface.

    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE
    3.
    发明授权
    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE 有权
    改进的透皮给药系统用于管理的罗替戈汀

    公开(公告)号:EP1524975B9

    公开(公告)日:2012-02-22

    申请号:EP03766331.7

    申请日:2003-07-28

    申请人: SCHWARZ PHARMA AG

    IPC分类号: A61K31/38 A61K9/70

    摘要: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.

    IMPROVED TRANSDERMAL DELIVERY SYSTEM
    4.
    发明公开
    IMPROVED TRANSDERMAL DELIVERY SYSTEM 有权
    改进的透皮给药系统

    公开(公告)号:EP1524971A1

    公开(公告)日:2005-04-27

    申请号:EP03766330.9

    申请日:2003-07-28

    申请人: SCHWARZ PHARMA AG

    IPC分类号: A61K9/70 A61K31/38

    摘要: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed priorto use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1)wherein an amine functional drug in its free base form has been incorporated, (2) which is saturated with the aminefunctional drug and contains said drug as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of the amine functional drug, (4) which is impermeable for the protonated form of the amine functional drug, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of the amine functional drug across the TDS/skin interface.

    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE
    5.
    发明公开
    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE 有权
    改进的透皮给药系统用于管理的罗替戈汀

    公开(公告)号:EP1524975A1

    公开(公告)日:2005-04-27

    申请号:EP03766331.7

    申请日:2003-07-28

    申请人: SCHWARZ PHARMA AG

    IPC分类号: A61K31/38 A61K9/70

    摘要: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.

    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE
    10.
    发明授权
    IMPROVED TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE 有权
    改进的透皮给药系统用于管理的罗替戈汀

    公开(公告)号:EP1524975B1

    公开(公告)日:2006-04-05

    申请号:EP03766331.7

    申请日:2003-07-28

    申请人: SCHWARZ PHARMA AG

    IPC分类号: A61K31/38 A61K9/70

    摘要: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.